In a late-stage clinical trial, the jab was 94 percent effective in preventing severe illness in older adults with at least one underlying medical condition.
In a world-first, the Food and Drug Administration on Wednesday approved a vaccine to combat the respiratory syncytial virus, or RSV, for adults who are 60 and older. The vaccine, to be sold under the brand name Arexvy, is a single-dose shot made by the pharmaceutical giant GSK. In, the jab was 94 percent effective in preventing severe illness in older adults with at least one underlying medical condition.
RSV, typically associated with young children and infants, also poses a significant danger to older people, with an estimated 10,000 to 13,000 adults 65 and older dying as a result of infection in the U.S. every year. The GSK shot’s approval comes some 60 years after researchers began trying to develop a vaccine for the virus. “This really is a wonderful development,” Dr.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Baca lebih lajut »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Baca lebih lajut »
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Baca lebih lajut »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Baca lebih lajut »
US FDA approves first RSV vaccine from GSKThe U.S. Food and Drug Administration has approved GSK Plc's respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
Baca lebih lajut »